Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ioxitalamic Acid SCHEMBL29815239 | 1.00 | LMNA (0.57) | LMNASMN1; SMN2GAABRD4CYP2C19 | |
| SCHEMBL11522720 | 0.92 | LMNA (0.55) | LMNASMN1; SMN2BRD4CYP2C19HIF1A | |
| SCHEMBL11775063 | 0.91 | LMNA (0.51) | LMNASMN1; SMN2GAACYP2C19HIF1A | |
| SCHEMBL11178469 | 0.86 | ALDH1A1 (0.36) | LMNASMN1; SMN2CYP2C19HIF1AMAP2K2 | |
| SCHEMBL9395608 | 0.85 | LMNA (0.46) | LMNASMN1; SMN2BRD4CYP2C19HIF1A | |
| SCHEMBL30881050 | 0.85 | LMNA (0.60) | LMNASMN1; SMN2BRD4CYP2C19HIF1A | |
| SCHEMBL9659222 | 0.85 | LMNA (0.60) | LMNASMN1; SMN2BRD4CYP2C19HIF1A | |
| SCHEMBL11412072 | 0.85 | LMNA (0.41) | LMNASMN1; SMN2TSHRMAPK1 | |
| Ioxitalamic Acid SCHEMBL29730019 | 0.84 | SMN1; SMN2 (0.78) | LMNASMN1; SMN2GAACYP2C19HIF1A | |
| SCHEMBL8610004 | 0.84 | LMNA (0.40) | LMNASMN1; SMN2TSHRMAPK1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683579-A1 | RELIEVE BACK PAIN AND/OR REBUILDING INTERVERTERAL DISC | Yeung, Jeffrey E. (US) | 2026-01-28 | — | — | EP | claimed |
| WO-2024158529-A1 | RELIEVE BACK PAIN AND/OR REBUILDING INTERVERTERAL DISC | YEUNG JEFFREY E (US) | 2024-08-02 | — | — | WO | claimed |
| WO-2021238893-A1 | EFFICIENT AND EFFECTIVE TISSUE CLEARING AGENTS AND THEIR COMPOSITIONS | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2021-12-02 | — | — | WO | claimed |
| US-20210069352-A1 | IODINE-BASED PARTICLES | NANOPROBES, INC. | 2021-03-11 | — | — | US | claimed |
| WO-2017165841-A1 | IODINE-BASED PARTICLES | NANOPROBES, INC. (US) | 2017-09-28 | — | — | WO | claimed |
| US-20170274101-A1 | IODINE-BASED PARTICLES | NANOPROBES, INC. | 2017-09-28 | — | — | US | claimed |
| US-20160375234-A1 | TRANSPAPILLARY METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING BREAST CONDITIONS | ATOSSA THERAPEUTICS, INC. | 2016-12-29 | — | — | US | claimed |
| EP-3092027-A1 | TRANSPAPILLARY METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING BREAST CONDITIONS | Atossa Genetics Inc. (US) | 2016-11-16 | — | — | EP | claimed |
| US-9393325-B2 | Bioabsorbable co-filler for cerebrovascular aneurysms | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2016-07-19 | — | — | US | claimed |
| US-20160151124-A1 | IMPLANTABLE MARKERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-06-02 | — | — | US | claimed |
| US-5330739-A | Iodinated benzoyl acetals and ketals for x-ray imaging | STERLING WINTHROP INC. (US) | 1994-07-19 | — | — | US | claimed |
| US-5328404-A | Contrast agents | STERLING WINTHROP INC. (US) | 1994-07-12 | — | — | US | claimed |
| EP-0603922-A1 | Iodinated aroyloxy esters and their use as contrast agents in X-ray imaging | NanoSystems L.L.C. (US) | 1994-06-29 | — | — | EP | claimed |
| EP-0603917-A1 | Iodinated agents and X-ray imaging compositions containing them | NanoSystems L.L.C. (US) | 1994-06-29 | — | — | EP | claimed |
| EP-0603923-A1 | Iodinated aromatic acid derivatives and their use as contrast agents in X-ray imaging | NanoSystems L.L.C. (US) | 1994-06-29 | — | — | EP | claimed |
| EP-0601616-A1 | Iodinated aroyloxy carboxamides and contrast agents containing them | NanoSystems L.L.C. (US) | 1994-06-15 | — | — | EP | claimed |
| EP-0601617-A1 | Iodinated benzoyl acetals and ketals, and contrast agents containing them | NanoSystems L.L.C. (US) | 1994-06-15 | — | — | EP | claimed |
| US-5264610-A | X-ray contrast agents | STERLING WINTHROP INC. (US) | 1993-11-23 | — | — | US | claimed |
| US-5260478-A | Contrast agents in x-ray imaging compositions; medical diagnosis | STERLING WINTHROP INC. (US) | 1993-11-09 | — | — | US | claimed |
| WO-1980001244-A1 | X-RAY CONTRAST MEDIA SOLUTIONS | BYKGULDEN LOMBERG CHEM FAB (DE) | 1980-06-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170274101-A1 | IODINE-BASED PARTICLES | TPO, BRI3BP, INSRR | LMNA 3921/4885SMN1; SMN2 4574/4885GAA 2551/4885 |
| US-20210069352-A1 | IODINE-BASED PARTICLES | TPO, BRI3BP, INSRR | LMNA 3921/4885SMN1; SMN2 4574/4885GAA 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.